Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.81 Insider Own2.80% Shs Outstand47.40M Perf Week-4.54%
Market Cap1.71B Forward P/E- EPS next Y-3.05 Insider Trans-12.05% Shs Float45.13M Perf Month-8.28%
Income-120.20M PEG- EPS next Q-0.67 Inst Own76.90% Short Float12.68% Perf Quarter3.79%
Sales17.00M P/S100.74 EPS this Y1.10% Inst Trans0.68% Short Ratio5.71 Perf Half Y21.08%
Book/sh5.38 P/B6.72 EPS next Y-7.40% ROA-32.40% Target Price45.20 Perf Year127.66%
Cash/sh7.57 P/C4.77 EPS next 5Y- ROE-58.70% 52W Range15.28 - 45.02 Perf YTD17.57%
Dividend- P/FCF- EPS past 5Y- ROI-48.20% 52W High-19.46% Beta-
Dividend %- Quick Ratio11.70 Sales past 5Y- Gross Margin- 52W Low137.30% ATR1.79
Employees112 Current Ratio11.70 Sales Q/Q457.10% Oper. Margin- RSI (14)47.93 Volatility5.94% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q21.10% Profit Margin- Rel Volume0.37 Prev Close36.13
ShortableYes LT Debt/Eq0.13 EarningsAug 08 AMC Payout- Avg Volume1.00M Price36.26
Recom2.70 SMA20-2.44% SMA50-1.87% SMA20011.85% Volume268,184 Change0.36%
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Jul-17-18 03:01PM  Yet Another CRISPR Worry: What Should Investors Do? Motley Fool
Jul-16-18 07:31PM  [$$] New Research Prompts Selloff in Companies Using Crispr Technology The Wall Street Journal -7.12%
02:28PM  CRISPR gene editing can cause risky collateral DNA damage - study Reuters
01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
12:21PM  Gene-editing stocks tumble on concerns about DNA damage MarketWatch
Jul-10-18 09:37AM  Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far) Motley Fool
Jul-09-18 07:03PM  Cramer's lightning round: Calling bottom in Southwest Air... CNBC Videos
07:20AM  Free Technical Research on Edge Therapeutics and Three More Biotech Equities ACCESSWIRE
Jul-04-18 09:30AM  Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-03-18 11:05PM  A Deep Dive Into The Latest CRISPR Controversy: Heres What You Should Know Motley Fool
Jun-22-18 03:12PM  Editas Medicine Stock History: The Story Behind the CRISPR Gene-Editing Pioneer Motley Fool
09:36AM  Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia Zacks
Jun-21-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within TrustCo Bank Corp NY, Highwoods Properties, Enova International, Editas Medicine, United Insurance, and Cutera New Research Emphasizes Economic Growth GlobeNewswire
Jun-18-18 02:22PM  Is Gene Editing Dangerous? 4 Things You Should Know Motley Fool
09:30AM  Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-16-18 12:01AM  [$$] Gene-Editing Selloff Is Overdone Barrons.com
Jun-13-18 09:00AM  Editas Medicine to Participate in The JMP Securities Life Sciences Conference GlobeNewswire
08:01AM  Should CRISPR Stock Investors Worry About Cancer? Motley Fool
06:02AM  CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic Motley Fool
Jun-12-18 07:01AM  CRISPR-related stocks sink after report that gene-editing technology might cause cancer MarketWatch
Jun-11-18 04:57PM  Here's Why CRISPR Stocks are Getting Rocked Today Motley Fool -7.80%
04:25PM  Gene-Editing Startups Downplay Potential of Cancer Side Effect Bloomberg
04:20PM  Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study Investor's Business Daily
01:56PM  CRISPR stocks tank after research shows edited cells might cause cancer CNBC
Jun-08-18 04:05PM  Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May Motley Fool
03:31AM  FDA Creates Potential Buying Opportunity for CRSP Investopedia
Jun-07-18 08:00AM  3 Stocks That Could Put Apple's Returns to Shame Motley Fool
Jun-01-18 08:41AM  Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex Zacks
08:16AM  3 Common Denominators of My 3 Best-Performing Stocks of 2018 So Far Motley Fool
May-31-18 12:29PM  Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Zacks
10:09AM  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA Zacks
08:31AM  4 Reasons Not to Worry About Crispr Therapeutics AG's Latest Setback Motley Fool
08:20AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine ACCESSWIRE
07:55AM  Is Crispr Therapeutics Stock a Bad News Buy? Motley Fool
May-30-18 03:37PM  What Makes This CRISPR Stock Better Than the Rest? Motley Fool +6.40%
May-18-18 05:00PM  Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates GlobeNewswire -8.24%
May-16-18 07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-15-18 10:04AM  Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? Zacks
May-14-18 07:30AM  [$$] Gene-Editing Pioneers Back Beam Therapeutics The Wall Street Journal
May-11-18 07:20PM  Your Guide to Investing in Gene Editing Motley Fool
08:09AM  3 Growth Stocks for In-the-Know Investors Motley Fool
May-08-18 08:00AM  Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
May-07-18 06:55AM  Edited Transcript of EDIT earnings conference call or presentation 3-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-05-18 10:16AM  Editas Medicine Starts a "Transformative" Year on a High Note Motley Fool
May-03-18 05:50PM  Editas: 1Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces First Quarter 2018 Results and Update GlobeNewswire
May-02-18 12:19PM  What Diseases Could Gene Editing Cure? Motley Fool
May-01-18 04:56PM  Top Gene-Editing Stocks for Long-Term Investors Motley Fool
Apr-30-18 01:30PM  Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
08:25AM  Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-28-18 10:00AM  3 Stocks That Could Put NVIDIA's Returns to Shame Motley Fool
Apr-27-18 02:35PM  Exclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridge American City Business Journals
Apr-26-18 04:01PM  Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results GlobeNewswire
Apr-23-18 07:06PM  Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like? Simply Wall St.
Apr-20-18 05:12PM  Big Week in Tech for Amazon, Alphabet and Microsoft Yahoo Finance Video
Apr-18-18 10:29AM  Companies with women executives can help you do better in the stock market MarketWatch
Apr-03-18 09:32AM  Oops! CRISPR Concerns Turn Out to be a Big Nothingburger Motley Fool
Mar-28-18 09:00AM  Editas Medicine Names James C. Mullen as Chairman of the Board of Directors GlobeNewswire
Mar-25-18 09:31AM  3 Stocks That Could Double Your Money Motley Fool
Mar-22-18 07:30AM  New Research: Key Drivers of Growth for Editas Medicine, Magellan Health, The RMR Group, Marcus, Nordson, and USA Compression Partners, LP Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-16-18 06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool
Mar-15-18 05:09PM  Why CRISPR Therapeutics Slipped 10% on Thursday Motley Fool -5.23%
Mar-13-18 07:57AM  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics Zacks
07:30AM  Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS) ACCESSWIRE
07:20AM  Wired News Voyager Therapeutics Declared Longer-term Data from Phase-1b Trial Of VY-AADC for Advanced Parkinsons Disease ACCESSWIRE
Mar-09-18 08:01AM  Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno Zacks
Mar-08-18 04:53PM  Companies with women executives can help you do better in the stock market MarketWatch
12:25PM  Healthcare Heroes That Aren't Done Yet Zacks
12:11AM  Edited Transcript of EDIT earnings conference call or presentation 6-Mar-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-07-18 05:40PM  Editas Medicine Delivers Another Strong Quarter Motley Fool +9.99%
03:49PM  Here's Why Editas Medicine Inc. Ticked Up Today Motley Fool
Mar-06-18 04:49PM  Editas reports 4Q loss Associated Press
04:01PM  Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update GlobeNewswire
01:30PM  Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
08:35AM  Editas Medicine Q4 Earnings Preview Benzinga
Mar-05-18 12:00AM  [$$] Crispr gene editing ready for testing in humans Financial Times
Mar-02-18 08:45AM  3 Growth Stocks That Could Put Facebook's Returns to Shame Motley Fool +7.54%
Mar-01-18 04:17PM  Pentagon Lab Worries About CRISPR Bioattack As China Seeks Genome Lead Investor's Business Daily
Feb-28-18 09:00AM  Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases GlobeNewswire
Feb-27-18 04:01PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results GlobeNewswire
Feb-23-18 12:29PM  3 Top DNA Stocks to Consider Buying Now Motley Fool
10:31AM  Gilead's Latest Deal Is Good News for Biotechs Barrons.com
07:40AM  Orgenesis (ORGS): An Undervalued Small Cap Biotech Company Every Healthcare Investor Should Know About ACCESSWIRE
Feb-16-18 09:00AM  Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors GlobeNewswire
Feb-15-18 06:02AM  3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate Motley Fool
Feb-08-18 04:01PM  Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire -9.24%
Feb-05-18 07:04AM  All the Stocks I'm Selling If the Market Keeps Falling Motley Fool
Feb-02-18 03:10PM  Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases? Investor's Business Daily
Jan-30-18 12:03PM  Here's Why Editas Medicine Rose as Much as 15.7% Yesterday Motley Fool
08:33AM  Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher Zacks
Jan-27-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-25-18 04:00PM  Adverum Biotechnologies and Editas Medicine Extend Research Collaboration GlobeNewswire
Jan-24-18 08:00AM  Celgene's Been Selling Shares in This Biotech Motley Fool
Jan-23-18 03:50PM  2 Gene Editing Stocks SunTrust Recommends Benzinga
09:48AM  Forget Penny Stocks: Your Money Is Better Off in These 3 Companies Motley Fool
Jan-22-18 04:27PM  Here's Why Editas Medicine Gained as Much as 14.2% Today Motley Fool +13.88%
07:30AM  Market Trends Toward New Normal in Editas Medicine, Impinj, Neos Therapeutics, Nordson, National Western Life Group, and Square Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-16-18 07:34AM  CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again Motley Fool -6.19%
Jan-08-18 01:49PM  Editas lower on questions about Crispr efficacy CNBC Videos -10.63%
09:00AM  Editas Medicine Reports on Recent Progress and Announces EM22 Five-year Goals at J.P. Morgan Healthcare Conference GlobeNewswire
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myer VickeshChief Technology OfficerJul 18Option Exercise11.217,00078,4706,150Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 18Sale35.567,000248,8920Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Option Exercise0.657,0004,5504,000Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Sale35.717,000249,9800Jul 19 04:07 PM
Bosley KatrinePresident and CEOJul 02Sale36.298,333302,4411,285,299Jul 05 04:00 PM
Myer VickeshChief Technology OfficerJun 19Option Exercise11.217,00078,4707,000Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 19Sale38.397,000268,7300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Option Exercise0.657,0004,5504,300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Sale38.127,000266,8420Jun 20 04:57 PM
Albright CharlesChief Scientific OfficerJun 13Option Exercise16.5110,000165,10010,000Jun 15 04:16 PM
Albright CharlesChief Scientific OfficerJun 13Sale35.9810,000359,8000Jun 15 04:16 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Option Exercise24.603,00073,8003,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Sale37.103,000111,3000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Option Exercise6.487,00045,3605,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Sale39.287,000274,9700Jun 05 04:08 PM
Bosley KatrinePresident and CEOJun 01Sale37.558,333312,8731,293,632Jun 05 04:06 PM
Albright CharlesChief Scientific OfficerMay 23Option Exercise16.5110,000165,10010,000May 25 04:31 PM
Albright CharlesChief Scientific OfficerMay 23Sale35.0010,000350,0000May 25 04:31 PM
MULLEN JAMES CDirectorMay 18Buy38.0310,000380,25210,000May 22 05:28 PM
Hopfield JessicaDirectorMay 17Buy37.286,700249,7806,700May 21 04:27 PM
Bosley KatrinePresident and CEOMay 01Sale31.958,333266,2391,301,965May 03 05:31 PM
Bosley KatrinePresident and CEOApr 02Sale32.168,333267,9691,310,298Apr 04 04:05 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Option Exercise20.7228,000580,08022,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Sale37.8628,0001,059,9600Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Sale37.656,000225,9000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Sale39.436,000236,5800Mar 20 05:36 PM
Bosley KatrinePresident and CEOMar 09Sale45.009,134411,0301,318,631Mar 13 08:45 AM
Bosley KatrinePresident and CEOMar 01Sale35.728,333297,6931,327,765Mar 05 04:52 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Sale35.326,000211,9200Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale34.616,000207,6600Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Sale32.716,000196,2600Feb 16 04:04 PM
Bosley KatrinePresident and CEOFeb 01Sale36.188,333301,4511,336,098Feb 05 06:05 PM
Bosley KatrinePresident and CEOJan 30Sale40.0510,000400,5201,344,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 29Sale37.5310,000375,3401,354,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 23Sale35.283,338117,7651,364,431Jan 25 04:11 PM
Bosley KatrinePresident and CEOJan 03Sale35.046,662233,4161,367,769Jan 04 04:09 PM
Bosley KatrinePresident and CEOJan 02Sale33.448,333278,6371,374,431Jan 04 04:09 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Option Exercise3.234,64915,0164,649Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Sale25.064,649116,5100Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Sale24.685,000123,4090Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Sale24.315,000121,5460Dec 19 04:38 PM
Bosley KatrinePresident and CEODec 01Sale29.588,333246,5221,382,764Dec 05 06:08 AM
Hack Andrew A. F.Chief Financial OfficerNov 20Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 20Sale25.355,000126,7320Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Sale24.815,000124,0730Nov 21 04:04 PM
Bosley KatrinePresident and CEONov 01Sale23.648,333196,9661,391,097Nov 03 04:48 PM
Bosley KatrinePresident and CEOOct 02Sale24.788,333206,5251,399,430Oct 04 04:30 PM
Bosley KatrinePresident and CEOSep 05Sale20.206,666134,6811,407,763Sep 06 05:05 PM
Bosley KatrinePresident and CEOSep 01Sale20.4210,000204,1501,414,429Sep 06 05:05 PM
Bosley KatrinePresident and CEOAug 11Sale20.026,666133,4501,424,429Aug 14 04:35 PM
Bosley KatrinePresident and CEOAug 10Sale20.0210,000200,1601,431,095Aug 14 04:35 PM